Shankar  Musunuri net worth and biography

Shankar Musunuri Biography and Net Worth

CEO of Ocugen
Dr. Musunuri is a seasoned biotech veteran with more than 25 years of results-driven experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, Dr. Musunuri held leadership roles at numerous companies ranging from "Big Pharma" to novel start-up biotechs. Most recently, he founded Nuron Biotech, Inc., which he grew to a commercial company in less than three years, serving as President and CEO. Dr. Musunuri spent nearly fifteen years at Pfizer, where he gained extensive product launch and life-cycle management experience, playing a key role as Global Operations Team Leader for the most successful launch in vaccine history, Prevnar 13®. Prior to Pfizer, he was a group leader focused on Phase 3 clinical development at Amylin Pharmaceuticals.

Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University’s Fuqua School of Business. He is a recipient of the Distinguished Alumnus Award from the University of Connecticut’s School of Pharmacy and serves on the Advisory Board of Fuqua’s Center for Entrepreneurship and Innovation at Duke University.

What is Shankar Musunuri's net worth?

The estimated net worth of Shankar Musunuri is at least $3.50 million as of January 17th, 2023. Dr. Musunuri owns 2,227,950 shares of Ocugen stock worth more than $3,497,882 as of April 16th. This net worth approximation does not reflect any other investments that Dr. Musunuri may own. Additionally, Dr. Musunuri receives a salary of $1,200,000.00 as CEO at Ocugen. Learn More about Shankar Musunuri's net worth.

How old is Shankar Musunuri?

Dr. Musunuri is currently 60 years old. There are 3 older executives and no younger executives at Ocugen. Learn More on Shankar Musunuri's age.

What is Shankar Musunuri's salary?

As the CEO of Ocugen, Inc., Dr. Musunuri earns $1,200,000.00 per year. Learn More on Shankar Musunuri's salary.

How do I contact Shankar Musunuri?

The corporate mailing address for Dr. Musunuri and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Shankar Musunuri's contact information.

Has Shankar Musunuri been buying or selling shares of Ocugen?

Shankar Musunuri has not been actively trading shares of Ocugen within the last three months. Most recently, Shankar Musunuri sold 100,000 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $1.28, for a transaction totalling $128,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,227,950 shares of the company's stock, valued at $2,851,776. Learn More on Shankar Musunuri's trading history.

Who are Ocugen's active insiders?

Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Are insiders buying or selling shares of Ocugen?

In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 200,278 shares worth more than $100,139.00. The most recent insider tranaction occured on June, 14th when Director Junge Zhang bought 200,278 shares worth more than $100,139.00. Insiders at Ocugen own 3.5% of the company. Learn More about insider trades at Ocugen.

Information on this page was last updated on 6/14/2023.

Shankar Musunuri Insider Trading History at Ocugen

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/17/2023Sell100,000$1.28$128,000.002,227,950View SEC Filing Icon  
10/14/2022Sell100,000$1.66$166,000.00752,540View SEC Filing Icon  
7/14/2022Sell150,000$2.72$408,000.00752,540View SEC Filing Icon  
5/13/2022Sell125,000$1.92$240,000.00752,540View SEC Filing Icon  
3/16/2022Sell81,823$2.65$216,830.95View SEC Filing Icon  
12/16/2021Sell115,000$5.22$600,300.00View SEC Filing Icon  
11/16/2021Sell115,000$8.04$924,600.00View SEC Filing Icon  
11/1/2021Sell115,367$14.15$1,632,443.05View SEC Filing Icon  
10/15/2021Sell125,000$9.80$1,225,000.00View SEC Filing Icon  
9/15/2021Sell125,000$7.52$940,000.00View SEC Filing Icon  
6/7/2021Sell7,758$10.94$84,872.52413,758View SEC Filing Icon  
5/3/2021Sell195,809$14.24$2,788,320.16601,809View SEC Filing Icon  
12/12/2019Buy406,000$0.34$138,040.00263,000View SEC Filing Icon  
See Full Table

Shankar Musunuri Buying and Selling Activity at Ocugen

This chart shows Shankar Musunuri's buying and selling at Ocugen by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ocugen Company Overview

Ocugen logo
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $1.59
Low: $1.52
High: $1.60

50 Day Range

MA: $1.16
Low: $0.52
High: $1.88

2 Week Range

Now: $1.59
Low: $0.35
High: $2.11

Volume

2,980,150 shs

Average Volume

8,161,378 shs

Market Capitalization

$407.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.51